RFC4 and hepatocellular carcinoma: In GSK461364, SB‐225002‐treated patients, non‐responders in breast, head and neck, and hepatocellular carcinoma patients were characterized by high expression of RFC4, and the area under the curve (AUC) values of OS exceeded 0.5 in all cohorts (Figure S14).